Synonyms: PA-824 | PA824
pretomanid is an approved drug (FDA (2019), EMA (2020))
Compound class:
Synthetic organic
Comment: Pretomanid is a nitroimidazole-based antibacterial used for the treatment of multi-drug-resistant pulmonary tuberculosis [3]. It is active against replicating and non-replicating Mycobacterium tuberculosis [1]. Pretomanid was developed by the non-profit organisation TB Alliance (www.tballiance.org.za).
|
|
References |
1. Aher RB, Sarkar D. (2021)
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating Mycobacterium tuberculosis. J Biomol Struct Dyn, 39 (3): 889-900. [PMID:31983295] |
2. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J et al.. (2020)
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 382 (10): 893-902. [PMID:32130813] |
3. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN et al.. (2000)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 405 (6789): 962-6. [PMID:10879539] |
4. (2012)
Pretomanid. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury,. [PMID:31869193] |